Breaking News —
The open trial of Ad5-nCoV in 108 healthy adults showed promising results after 28 days.
A possible coronavirus vaccine developed in China has shown that it is safe, well tolerated and capable of generating neutralizing antibodies to SARS-CoV-2 in dozens of patients in an early-stage clinical trial, according to a study published Friday in the The Lancet magazine.
The open trial in 108 adults healthy offered promising results after 28 days. The final results will be evaluated within six months.
The possible vaccine, called Ad5-nCoV, It was developed by the Beijing Institute of Biotechnology and the Chinese company CanSino Biologic. It was approved for human testing in March. Participants were between 18 and 60 years old and received a low, medium or high dose. Each of the groups consisted of 36 people.
The scientists found that the concentration of neutralizing antibodies seemed to increase with the dose. By day 28, half of the patients in the low and medium dose groups had neutralizing antibodies compared to three quarters of the patients in the high dose group.
“These results represent a important milestone“Wei Chen, a professor at the Beijing Biotechnology Institute and lead author of the study, said Xinhua.” The trial shows that a single dose of the new vaccine. [Ad5-nCoV] produces specific antibodies against viruses and T cells in 14 days, making it a potential candidate for further research“Chen said.
However, the scientist called for interpreting these results “with caution”. “The challenges in developing a covid-19 vaccine are unprecedented, and the ability to trigger these immune responses does not necessarily indicate that the vaccine will protect humans from covid-19,” Chen warned, adding that the world is still it is “very far from making this vaccine available to everyone.”
If you found it interesting, share it with your friends!